FDA Enforcement Trends: Unauthorized Nicotine Products 2026

In September 2025, U.S. Marshals and ATF agents seized 2.1 million illicit vaping products from 11 companies across seven states. Every one of those companies had already received an FDA warning letter. They kept selling anyway. FDA escalated.

That sweep was part of a pattern that nicotine product manufacturers and their ingredient suppliers need to understand: FDA enforcement in 2026 is shifting from retail-level warnings to supply chain-level interdiction. The agency has $200 million in dedicated enforcement funding, new port-of-entry destruction authority, and a proposed rule tying every imported nicotine product shipment to a specific PMTA tracking number. The paper trail from ingredient to finished product is now the critical compliance artifact.

For ingredient suppliers, the question is no longer whether your customers will face enforcement scrutiny. It is whether the documentation you provide can withstand it.

The Numbers Behind FDA's 2026 Enforcement Posture

FDA's Center for Tobacco Products has issued over 700 warning letters to firms manufacturing, selling, or distributing unauthorized tobacco products. An additional 100+ warning letters have gone specifically to firms dealing in unauthorized non-tobacco nicotine (NTN) products. On the retail side, more than 800 warning letters have reached brick-and-mortar and online retailers selling unauthorized products.

The civil money penalty (CMP) pipeline is equally active: 96 CMP complaints filed against manufacturers, with 70 manufacturers and 160 retailers targeted overall.

The most telling statistic: FDA completed initial review of 95% of NTN product applications. Of those, 889,000+ products received Refuse to Accept (RTA) letters. Approximately 1,600 applications were accepted for substantive review. The number of NTN products that have received marketing authorization? Zero. Every NTN product currently on the US market is technically illegal under federal law.

FDA has stated the position plainly: "All NTN products on the market are marketed unlawfully and risk FDA enforcement action."

From Warning Letters to Seizures: How Enforcement Is Escalating

The enforcement escalation pattern follows a predictable sequence: warning letter, follow-up inspection, continued non-compliance, then injunction or seizure. FDA and DOJ have initiated eight permanent injunction proceedings against e-cigarette manufacturers since October 2022. One company, Soul Vapor LLC, was targeted twice.

Port-of-Entry Seizures Set New Records

The most significant enforcement shift in 2025 was at the border. In February 2025, FDA and CBP seized approximately 2 million unauthorized e-cigarette units in Chicago, with an estimated retail value of $33.8 million. Nearly all originated in China.

Then in September 2025, the largest-ever seizure operation stopped 4.7 million units worth $86.5 million across Arizona, Florida, Georgia, Illinois, New Jersey, and North Carolina. The 2025 year-to-date total exceeded 6 million units and $120 million in retail value.

FDA also sent its first-ever import informational letters to 24 tobacco importers and customs entry filers responsible for importing unauthorized products. Many shipments contained vague product descriptions with incorrect declared values, an apparent attempt to evade duties and import review.

Import Alerts Now Enable Detention Without Physical Examination

Updated in January 2025, Import Alert 98-07 covers ENDS products and allows any unauthorized e-cigarette to be detained without physical examination and refused admission. Import Alert 98-06 covers other tobacco products, including unauthorized smokeless tobacco and nicotine pouches. The alerts were separated specifically to give clearer instructions to field staff, customs brokers, importers, and entry filers.

For manufacturers sourcing nicotine ingredients through import channels, these alerts mean that shipment documentation must be precise, complete, and verifiable at the point of entry. Ambiguity in product descriptions or missing authorization data is now a trigger for detention, not just a compliance gap to address later.

$200 Million and a New Interagency Task Force

The FY2026 Agriculture-FDA appropriations bill directs at least $200 million of tobacco user-fee funds toward ENDS enforcement. Within CTP's total budget of $712 million and approximately 800 staff, that $200 million represents a decisive commitment to enforcement over other priorities.

Congress also earmarked $2 million for an interagency task force combining FDA, DOJ, and DHS. The task force targets unauthorized nicotine products "particularly at border crossings and distribution hubs." FDA's Commissioner received authority to detain and destroy illegal e-cigarette products seized at ports of entry. Previously, seized products had to be returned. The shift has been described as moving "from passive oversight to proactive interdiction."

The practical implication: enforcement is no longer constrained by CTP's historically limited staff. Multi-agency coordination brings DHS border resources and DOJ prosecution capacity into the enforcement pipeline. When a nicotine product shipment arrives at a US port without proper documentation, the responding agencies now have authority, funding, and infrastructure to act immediately.

The ACE Tracking Number Rule: Linking Shipments to PMTAs

A proposed rule published in the Federal Register on August 16, 2024 (Docket: FDA-2024-N-1111) would require importers of ENDS products to provide a PMTA Submission Tracking Number (STN) at the time of entry in the Automated Commercial Environment (ACE) system. Currently, providing the STN is optional. The rule would make it mandatory.

Each imported shipment would be directly linked to a specific PMTA application, enabling automated admissibility review by FDA's import systems. Products without a valid STN would be flagged for detention or refusal at the border. The rule would make it "significantly more difficult for unauthorised products to enter the US through legitimate customs channels."

The comment period closed October 15, 2024. As of April 2026, the final rule is pending. The direction is clear: FDA is building automated systems that connect product documentation to physical shipments in real time.

Enforcement Is Moving Upstream Through the Supply Chain

The most consequential trend for ingredient suppliers is the directional shift in enforcement targets.

Early enforcement from 2020 through 2023 focused primarily on retailers selling unauthorized products. In February 2023, FDA filed its first CMP complaints against manufacturers. By September 2025, enforcement escalated to distributors, with five targeted in the nationwide seizure sweep. That same year brought the first import informational letters to importers and customs entry filers.

The pattern is unmistakable: enforcement is moving upstream, from point of sale to point of manufacture and import. FDA's own registration and listing modernization efforts reinforce this direction. New Form FDA 3741 consolidates registration forms and adds a Universal Product Code field for traceability. The stated goal is "clearer visibility into who is manufacturing what, where products are being made, and how they move through the supply chain."

For ingredient suppliers, this means your documentation is no longer several steps removed from enforcement activity. When FDA traces an unauthorized product back through its supply chain, the ingredient supplier's records are part of what they find, or fail to find.

The CMP Constitutional Challenge

One complicating factor: in August 2025, a U.S. District Court in the Northern District of Texas ruled FDA's tobacco CMP provisions unconstitutional. The D.C. Circuit heard oral argument in December 2025. Despite this challenge, FDA has continued filing hundreds of new CMP complaints.

If CMPs are ultimately limited by the courts, FDA may lean more heavily on injunctions and seizures, both of which operate at the supply chain level. The net effect could be to accelerate, not slow, the enforcement shift toward manufacturers, distributors, importers, and their suppliers.

What This Means for Ingredient Documentation

FDA enforcement in 2026 is increasingly data-driven, tied directly to PMTA status through Marketing Denial Orders (MDOs) and Refuse to File (RTF) decisions. Regulatory analysts describe it as enforcement "aligned with regulatory outcomes," where MDOs and RTFs serve as a roadmap for targeted enforcement activity.

For nicotine ingredient suppliers, this alignment creates specific documentation requirements. Under 21 CFR Part 1114, PMTA submissions must include for each ingredient: the ingredient name (IUPAC or common chemical name), CAS number, purity and grade with supplier identity, target quantity and range with unit of measure, manufacturing methods and controls, and evidence of batch-to-batch consistency.

Starting January 2, 2026, all PMTA and Substantial Equivalence submissions must use FDA's latest web-based application forms. Applications submitted in outdated formats are subject to Refuse to Accept.

Eight Documentation Capabilities Your Customers Need From You

Based on current enforcement patterns and PMTA requirements, ingredient suppliers should be able to provide:

1. Certificates of Analysis for every batch. Including purity, grade, contaminant testing, and CAS numbers. A USP/EP grade nicotine CoA with full impurity profiling is the documentation standard FDA expects in PMTA ingredient submissions.

2. Full traceability documentation. Lot numbers, manufacturing dates, and chain of custody from production through delivery. When FDA traces an unauthorized product upstream, this is the documentation trail they follow.

3. Consistent product specifications. Documented target ranges that match what customers declare in their PMTA applications. Specification drift between what the supplier provides and what the PMTA states creates a deficiency that FDA will identify during review.

4. Supplier identity verification. Clear legal entity name, facility addresses, and registration status. The registration modernization efforts are designed to give FDA visibility into exactly this information.

5. Stability and shelf-life data. Supporting long-term product characterization that demonstrates ingredient specifications hold through the product's declared shelf life.

6. USP/EP grade compliance documentation. For pharmaceutical-grade nicotine, this includes monograph compliance records that satisfy both FDA and international regulatory frameworks. Nicotine salts and other derivative forms each require grade-specific documentation.

7. Change notification protocols. A documented process for notifying customers of any specification changes that could affect their PMTA. An undocumented specification change that surfaces during FDA review can trigger a deficiency letter for your customer.

8. Regulatory correspondence readiness. The ability to respond rapidly to FDA information requests during PMTA review. Multi-year reviews routinely generate supplemental information requests. Response time and documentation quality shape how those reviews proceed.

The Supply Chain Accountability Thesis

FDA is moving from what enforcement observers call "whack-a-mole" retail enforcement to structural supply chain controls. The ACE tracking number rule, registration modernization, import alert updates, and the $200 million enforcement budget all create documentation checkpoints throughout the supply chain.

The ingredient supplier sits at a critical node in this chain. Manufacturers who submit PMTAs need their ingredient documentation to be precise, consistent, and auditable. When that documentation comes from a US-based supplier with a certified manufacturing partner, the compliance path is shorter: no import documentation complexity, faster response to FDA supplemental requests, and manufacturing partner audits accessible on shorter notice.

The contrast with undocumented offshore sourcing is stark. Building supply chain traceability retroactively during an active PMTA review is a liability, not a documentation exercise. As the PMTA fast-track pilot cancellation demonstrated, full 21 CFR Part 1114 review is the only pathway, and the evidentiary requirements are higher than what any pilot program relaxed.

Ingredient suppliers who provide robust, PMTA-ready documentation give their customers a compliance advantage. When FDA uses MDOs and RTFs as a roadmap for targeted action, that advantage is the difference between a product that survives enforcement scrutiny and one that does not.

If your current ingredient documentation would not survive an FDA trace-back from a finished product to your batch records, that gap needs to close before enforcement reaches your position in the supply chain. NicAlliance provides USP/EP grade nicotine and nicotine dilutions with full batch documentation, CoA transparency, and PMTA-ready traceability records. Request a sample with complete documentation to benchmark against your current supplier's package.

Frequently Asked Questions